Nicholas Keher

Investec Bank Plc (Broker) (IBP) is the brokerage arm of Investec Bank Plc, itself a subsidiary of Investec Plc (LON: INVP) in Great Britain. Headquartered in London, IBP was founded in 1950 and they offer a full spectrum of brokerage services specifically tailored for corporate clients.

RBC Europe Ltd. is the Great Britain-based broker/dealer subsidiary of RBC Europe Ltd., itself a subsidiary of Royal Bank of Canada (TSE: RY) in Canada. Headquartered in London, the firm was founded in 1970 and provides a full spectrum of brokerage services specifically tailored for both retail and institutional investors. The firm is active in several markets, exchanges, and electronic trading platforms.

Clinigen Ltd. engages in the provision of pharmaceutical products and services. It operates through the following segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires rights to niche hospital-only and critical care products and also provides access to licensed and branded generic. The Unlicensed Medicines segment supplies unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Trial Services offers comparator medicines and services to clinical trials and IITs. The company was founded by Andrew Leaver in June 2010 and is headquartered in Burton-on-Trent, the United Kingdom.

Part of Triley Bidco Ltd., Idis Group Holdings Ltd. is a holding British company. The company is based in Burton-on-Trent, UK. Founded in 2005, Idis Group Holdings operates as a holding company.

Idis Ltd. supplies pharmaceuticals and allied services to the healthcare industry. the company was founded by Crane Michael and Gould Amanda in 1987 and is headquartered in Weybridge, The united kingdom

Part of Iovance Biotherapeutics, Inc., Clinigen SP Ltd. is a British pharmaceutical company that manufactures and sells pharmaceutical products. The company is based in Burton-On-Trent, UK. The company was founded in 2013. Clinigen was acquired by Iovance Biotherapeutics, Inc. from Clinigen Holdings Ltd. on May 18, 2023 for $264.04 million.